HomeCompareRNLX vs SBUX

RNLX vs SBUX: Dividend Comparison 2026

RNLX yields 965.72% · SBUX yields 2.75%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 RNLX wins by $13912651.09M in total portfolio value
10 years
RNLX
RNLX
● Live price
965.72%
Share price
$0.21
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$13912651.24M
Annual income
$11,558,252,316,743.19
Full RNLX calculator →
SBUX
SBUX
● Live price
2.75%
Share price
$89.59
Annual div
$2.46
5Y div CAGR
48.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$157.5K
Annual income
$65,840.13
Full SBUX calculator →

Portfolio growth — RNLX vs SBUX

📍 RNLX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodRNLXSBUX
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, RNLX + SBUX cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
RNLX pays
SBUX pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

RNLX
Annual income on $10K today (after 15% tax)
$82,085.95/yr
After 10yr DRIP, annual income (after tax)
$9,824,514,469,231.71/yr
SBUX
Annual income on $10K today (after 15% tax)
$233.40/yr
After 10yr DRIP, annual income (after tax)
$55,964.11/yr
At 15% tax rate, RNLX beats the other by $9,824,514,413,267.60/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of RNLX + SBUX for your $10,000?

RNLX: 50%SBUX: 50%
100% SBUX50/50100% RNLX
Portfolio after 10yr
$6956325.70M
Annual income
$5,779,126,191,291.66/yr
Blended yield
83.08%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on SBUX right now

RNLX
Analyst Ratings
4
Buy
Consensus: Buy
Price Target
$2.00
+865.7% upside vs current
Range: $2.00 — $2.00
Altman Z
-81.2
Piotroski
4/9
SBUX
Analyst Ratings
28
Buy
27
Hold
3
Sell
Consensus: Buy
Price Target
$104.00
+16.1% upside vs current
Range: $90.00 — $120.00
Altman Z
2.6
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

RNLX buys
0
SBUX buys
0
No recent congressional trades found for RNLX or SBUX in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricRNLXSBUX
Forward yield965.72%2.75%
Annual dividend / share$2.00$2.46
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%48.3%
Portfolio after 10y$13912651.24M$157.5K
Annual income after 10y$11,558,252,316,743.19$65,840.13
Total dividends collected$13731859.26M$127.5K
Payment frequencyquarterlyquarterly
SectorStockConsumer Discretionary
Analyst consensusBuyBuy
Analyst price target$2.00$104.00

Year-by-year: RNLX vs SBUX ($10,000, DRIP)

YearRNLX PortfolioRNLX Income/yrSBUX PortfolioSBUX Income/yrGap
1← crossover$107,272$96,571.70$11,107$407.21+$96.2KRNLX
2$1,082,950$968,169.28$12,512$626.87+$1.07MRNLX
3$10,293,382$9,134,625.57$14,366$978.69+$10.28MRNLX
4$92,157,965$81,144,045.78$16,929$1,557.50+$92.14MRNLX
5$777,574,449$678,965,426.88$20,658$2,543.80+$777.55MRNLX
6$6,185,938,370$5,353,933,709.94$26,406$4,302.22+$6185.91MRNLX
7$46,425,346,428$39,806,392,371.93$35,877$7,622.00+$46425.31MRNLX
8$328,877,172,876$279,202,052,197.87$52,741$14,352.64+$328877.12MRNLX
9$2,200,372,827,971$1,848,474,252,993.64$85,676$29,243.03+$2200372.74MRNLX
10$13,912,651,242,672$11,558,252,316,743.19$157,513$65,840.13+$13912651.09MRNLX

RNLX vs SBUX: Complete Analysis 2026

RNLXStock

Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data from electronic health record systems to generate a unique patient risk score. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. Renalytix AI plc has a license agreement with Mount Sinai Health System to develop and commercialize licensed products in connection with the application of artificial intelligence for the diagnosis of kidney disease; Joslin Diabetes Center, Inc. for developing and commercializing products for diagnosing and predicting kidney disease using biomarkers; and Kantaro Biosciences LLC for developing and commercializing laboratory tests for the detection of antibodies against SARS-CoV-2. The company also has a partnership agreement with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to implement an advanced clinical care model designed to improve kidney health and reduce kidney disease progression and kidney failure in high-risk populations. The company was formerly known as Renalytix AI plc and changed its name to Renalytix Plc in June 2021. Renalytix Plc was incorporated in 2018 and is headquartered in New York, New York.

Full RNLX Calculator →

SBUXConsumer Discretionary

Starbucks Corporation, together with its subsidiaries, operates as a roaster, marketer, and retailer of specialty coffee worldwide. The company operates through three segments: North America, International, and Channel Development. Its stores offer coffee and tea beverages, roasted whole beans and ground coffees, single serve products, and ready-to-drink beverages; and various food products, such as pastries, breakfast sandwiches, and lunch items. The company also licenses its trademarks through licensed stores, and grocery and foodservice accounts. The company offers its products under the Starbucks, Teavana, Seattle's Best Coffee, Evolution Fresh, Ethos, Starbucks Reserve, and Princi brands. As of October 3, 2021, it operated 16,826 company-operated and licensed stores in North America; and 17,007 company-operated and licensed stores internationally. The company was founded in 1971 and is based in Seattle, Washington.

Full SBUX Calculator →
📬

Get this RNLX vs SBUX comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

RNLX vs SCHDRNLX vs JEPIRNLX vs ORNLX vs KORNLX vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.